Worldwide post‐marketing safety surveillance experience with tofacitinib in ulcerative colitis

BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Post‐marketing surveillance (PMS) is an important part of monitoring adverse events (AEs). AIMS: To report an analysis of PMS case safety reports for tofacitinib in patients with UC METHODS: World...

Descripción completa

Detalles Bibliográficos
Autores principales: Rubin, David T., Modesto, Irene, Vermeire, Séverine, Danese, Silvio, Ng, Siew C., Kwok, Kenneth K., Koram, Nana, Jones, Thomas V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Post‐marketing Safety of Tofacitinib in Ulcerative Colitis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293472/
https://www.ncbi.nlm.nih.gov/pubmed/34626429
http://dx.doi.org/10.1111/apt.16619

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293472/
https://www.ncbi.nlm.nih.gov/pubmed/34626429
http://dx.doi.org/10.1111/apt.16619

Ejemplares similares